AlphaRx, Inc. ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

AlphaRx, Inc. ' Product Pipeline Review ' 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's pharmaceuticals report, 'AlphaRx, Inc. - Product Pipeline Review - 2012' provides data on the AlphaRx, Inc.'s
research and development focus. The report includes information on current developmental pipeline, complete with latest updates,
and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, AlphaRx, Inc.'s corporate
website, SEC filings, investor presentations and featured press releases, both from AlphaRx, Inc. and industry-specific third party
sources, put together by Global Markets Direct's team.

Scope

- AlphaRx, Inc. - Brief AlphaRx, Inc. overview including business description, key information and facts, and its locations and
subsidiaries.
- Review of current pipeline of AlphaRx, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of AlphaRx, Inc. with complete description of the product's developmental
history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the AlphaRx, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate AlphaRx, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of AlphaRx, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AlphaRx, Inc.'s R&D portfolio and develop key strategic initiatives to
reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with AlphaRx, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of AlphaRx, Inc. and identify potential opportunities in those areas.

AlphaRx, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
AlphaRx, Inc. Snapshot 6
AlphaRx, Inc. Overview 6
Key Information 6
Key Facts 6
AlphaRx, Inc. ' Research and Development Overview 7
Key Therapeutic Areas 7
AlphaRx, Inc. ' Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products ' Monotherapy 11
AlphaRx, Inc. ' Pipeline Products Glance 12
AlphaRx, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
AlphaRx, Inc. ' Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
AlphaRx, Inc. ' Drug Profiles 15
ARX-181 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ARX606T 16
R&D Progress 16
ARX8103 17
R&D Progress 17
ARX8203 18
R&D Progress 18
ARX828 20
R&D Progress 20
Cipro NDS 21
R&D Progress 21



Indaflex 22
R&D Progress 22
Streptomycin NDS 24
R&D Progress 24
Teposolin 25
R&D Progress 25
Vansolin 26
R&D Progress 26
AlphaRx, Inc. ' Pipeline Analysis 27
AlphaRx, Inc. ' Pipeline Products by Therapeutic Class 27
AlphaRx, Inc. ' Pipeline Products by Route of Administration 28
AlphaRx, Inc. ' Pipeline Products By Mechanism of Action 29
AlphaRx, Inc. ' Recent Pipeline Updates 31
AlphaRx, Inc. - Dormant Projects 32
AlphaRx, Inc. ' Company Statement 33
AlphaRx, Inc. ' Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
AlphaRx, Inc., Recent Developments 37
AlphaRx, Inc.- Press Release 37
Sep 14, 2009: AlphaRx Presents Company Overview And New Product Candidates At The Rodman & Renshaw Healthcare
Conference 37
Aug 17, 2009: AlphaRx Completes Lyophilization Process For Zysolin 37
Jul 23, 2009: AlphaRx Presents Positive Preclinical Data On Zysolin Inhalable Nanoparticles At Controlled Release Society Annual
Meeting 38
Jun 18, 2009: Zysolin Pre-clinical Data Supports Once-A-Day Dosing In Humans 39
Financial Deals Landscape 40
AlphaRx, Inc., Deals Summary 40
AlphaRx, Inc., Pharmaceuticals & Healthcare, Deal Details 41
Partnerships 41
AlphaRx Enters Into Joint Venture With Venturepharm 41
AlphaRx Enters Into Research And Development Agreement With USAMRIID 42
Anti Aging Medical Group Enters Into Collaboration Agreement With AlphaRX 43
AlphaRx Enters Into Co-Development Agreement PharmaSeed 44
AlphaRx International Forms Joint Venture With China Lianyungang 45
Licensing Agreements 46
AlphaRx Enters Into An Agreement With Riso Pharma 46
AlphaRx Enters Into Licensing Agreement With Gaia BioPharma 48
AlphaRx Enters Into Licensing Agreement With Proprius Pharma For Indaflex 49
Equity Offering 50



AlphaRx Canada Announces Private Placement Of $1.49 Million 50
AlphaRx Completes Private Placement Of $0.5 Million 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables

AlphaRx, Inc., Key Information 6
AlphaRx, Inc., Key Facts 6
AlphaRx, Inc. ' Pipeline by Indication, 2012 9
AlphaRx, Inc. ' Pipeline by Stage of Development, 2012 10
AlphaRx, Inc. ' Monotherapy Products in Pipeline, 2012 11
AlphaRx, Inc. ' Phase II, 2012 12
AlphaRx, Inc. ' Pre-Clinical, 2012 13
AlphaRx, Inc. ' Discovery, 2012 14
AlphaRx, Inc. ' Pipeline By Therapeutic Class, 2012 27
AlphaRx, Inc. ' Pipeline By Route of Administration, 2012 28
AlphaRx, Inc. ' Pipeline Products By Mechanism of Action, 2012 30
AlphaRx, Inc. ' Recent Pipeline Updates, 2012 31
AlphaRx, Inc. - Dormant Developmental Projects,2012 32
AlphaRx, Inc., Subsidiaries 36
AlphaRx, Inc., Deals Summary 40
AlphaRx Enters Into Joint Venture With Venturepharm 41
AlphaRx Enters Into Research And Development Agreement With USAMRIID 42
Anti Aging Medical Group Enters Into Collaboration Agreement With AlphaRX 43
AlphaRx Enters Into Co-Development Agreement PharmaSeed 44
AlphaRx International Forms Joint Venture With China Lianyungang 45
AlphaRx Enters Into An Agreement With Riso Pharma 46
AlphaRx Enters Into Licensing Agreement With Gaia BioPharma 48
AlphaRx Enters Into Licensing Agreement With Proprius Pharma For Indaflex 49
AlphaRx Canada Announces Private Placement Of $1.49 Million 50
AlphaRx Completes Private Placement Of $0.5 Million 51

List of Figures

AlphaRx, Inc. ' Pipeline by Indication, 2012 8
AlphaRx, Inc. ' Pipeline by Stage of Development, 2012 10
AlphaRx, Inc. ' Monotherapy Products in Pipeline, 2012 11
AlphaRx, Inc. ' Pipeline By Route of Administration, 2012 28
AlphaRx, Inc. - Pipeline Products By Mechanism of Action, 2012 29


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


AlphaRx, Inc. ' Product Pipeline Review ' 2012

Recomendados

Recomendados

Mais conteúdo relacionado

Destaque

Destaque (13)

Mais de ReportLinker.com

Mais de ReportLinker.com (20)

AlphaRx, Inc. ' Product Pipeline Review ' 2012